163 related articles for article (PubMed ID: 28835741)
41. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
[TBL] [Abstract][Full Text] [Related]
42. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
43. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
[TBL] [Abstract][Full Text] [Related]
44. A discrete-choice experiment to assess treatment modality preferences of patients with depression.
Lokkerbol J; Geomini A; van Voorthuijsen J; van Straten A; Tiemens B; Smit F; Risseeuw A; Hiligsmann M
J Med Econ; 2019 Feb; 22(2):178-186. PubMed ID: 30501437
[TBL] [Abstract][Full Text] [Related]
45. Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.
Harrison M; Marra C; Shojania K; Bansback N
Rheumatology (Oxford); 2015 Oct; 54(10):1816-25. PubMed ID: 25989956
[TBL] [Abstract][Full Text] [Related]
46. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
[TBL] [Abstract][Full Text] [Related]
47. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
48. Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.
Wicks P; Brandes D; Park J; Liakhovitski D; Koudinova T; Sasane R
Interact J Med Res; 2015 Mar; 4(1):e6. PubMed ID: 25749630
[TBL] [Abstract][Full Text] [Related]
49. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
50. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
Morel T; Aymé S; Cassiman D; Simoens S; Morgan M; Vandebroek M
Orphanet J Rare Dis; 2016 May; 11(1):70. PubMed ID: 27225337
[TBL] [Abstract][Full Text] [Related]
51. Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments.
Poulos C; Hauber AB; González JM; Turpcu A
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1008-15. PubMed ID: 24339373
[TBL] [Abstract][Full Text] [Related]
52. Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data.
Nicholas JA; Electricwala B; Lee LK; Johnson KM
BMC Neurol; 2019 Oct; 19(1):258. PubMed ID: 31660897
[TBL] [Abstract][Full Text] [Related]
53. A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs.
Atkinson-Clark E; Charokopou M; Van Osselaer N; Hiligsmann M
Epilepsy Behav; 2018 Feb; 79():58-67. PubMed ID: 29248866
[TBL] [Abstract][Full Text] [Related]
54. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
[TBL] [Abstract][Full Text] [Related]
55. German travelers' preferences for travel vaccines assessed by a discrete choice experiment.
Poulos C; Curran D; Anastassopoulou A; De Moerlooze L
Vaccine; 2018 Feb; 36(7):969-978. PubMed ID: 29338877
[TBL] [Abstract][Full Text] [Related]
56. Survey of diagnostic and treatment practices for multiple sclerosis in Europe.
Fernández O; Delvecchio M; Edan G; Fredrikson S; Gionvannoni G; Hartung HP; Havrdova E; Kappos L; Pozzilli C; Soerensen PS; Tackenberg B; Vermersch P; Comi G
Eur J Neurol; 2017 Mar; 24(3):516-522. PubMed ID: 28139062
[TBL] [Abstract][Full Text] [Related]
57. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.
Lloyd A; McIntosh E; Price M
Pharmacoeconomics; 2005; 23(11):1167-81. PubMed ID: 16277551
[TBL] [Abstract][Full Text] [Related]
58. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Mühlbacher A; Bethge S
Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
[TBL] [Abstract][Full Text] [Related]
59. Physician preferences for bone metastasis drug therapy in Canada.
Arellano J; González JM; Qian Y; Habib M; Mohamed AF; Gatta F; Hauber AB; Posner J; Califaretti N; Chow E
Curr Oncol; 2015 Oct; 22(5):e342-8. PubMed ID: 26628874
[TBL] [Abstract][Full Text] [Related]
60. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
